



(51) International Patent Classification:

A61K 31/4162 (2006.01) *A61P 9/00* (2006.01)
A61K 31/616 (2006.01) *A61K 31/506* (2006.01)
A61P 7/02 (2006.01) *A61K 31/53* (2006.01)

(21) International Application Number:

PCT/US2024/025394

(22) International Filing Date:

19 April 2024 (19.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/497,111 19 April 2023 (19.04.2023) US

(71) Applicants: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventors: **LI, Danshi**; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **NESSEL, Christopher**; 555 US Highway 22 W, Bridgewater, New Jersey 08807 (US). **PLOTNIKOV, Alexei**; 555 US Highway 22

W, Bridgewater, New Jersey 08807 (US). **BARNATHAN, Elliot**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **MOHAN, Puneet**; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **HORROW, Jay**; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(74) Agent: **LODISE, Stephanie A.** et al.; BAKER-HOSTETLER, 1735 Market Street, Suite 3300, Philadelphia, Pennsylvania 19103-7501 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: USE OF MILVEXIAN FOR TREATING OR PREVENTING ADVERSE CEREBROVASCULAR EVENTS OR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS HAVING ACUTE CORONARY SYNDROME




FIG. 1

(57) Abstract: A Factor XIa inhibitor having therapeutic properties useful in methods for of preventing adverse cerebrovascular events or adverse cardiovascular events in human patients with acute coronary syndrome.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*